Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EpiCept Ceases Drug Discovery Operations, Cuts Workforce | Contract Pharma

What are you searching for?

Sign in
Breaking News

EpiCept Ceases Drug Discovery Operations, Cuts Workforce

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

EpiCept Corp. is discontinuing all drug discovery activities and reducing its workforce by approximately 65%. These actions are expected to reduce annual expenses by at least $5.5 million. EpiCept will direct its resources toward the registration of Ceplene in North America and clinical development programs. 

“This is a difficult decision and is largely attributable to the current financing environment, but in taking these actions we will help ensure that EpiCept has the resources to execute our development strategies for our most advanced opportunities,” stated Jack Talley, president and chief executive officer of EpiCept. “We are currently focused on partnering Ceplene in Europe and pursuing regulatory approval of Ceplene in the U.S. and Canada. In addition, we look forward to advancing our other drug candidates through key clinical trials, such as our Phase Ib development program for EPC 2407 in patients with advanced solid tumors and lymphomas.”

Under the layoff plan, affected positions will be eliminated immediately and the remainder will be eliminated during the next three to six months. The company expects to incur a one-time charge during 1Q09 of approximately $2.5 million related to the closing of the San Diego facility. EpiCept plans to sell the proprietary ASAP drug discovery technology or partner with an interested party.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics